Lytix Biopharma ASA (LYTIX) Earnings Call Transcripts

Lytix Biopharma ASA's Latest Earnings Call - Q1 FY2026

In Q1 2026, Lytix Biopharma ASA reported significant operational progress and strategic advancements, particularly in their neoadjuvant melanoma program with ruxotemitide. The company highlighted promising results from the ATLAS-IT-05 study, showcasing an abscopal effect in melanoma patients, which could enhance the drug's market potential. Financially, Lytix raised NOK 77.3 million, strengthening their balance sheet with cash and short-term investments totaling NOK 120 million, supporting ongoing clinical trials and strategic initiatives. No changes to guidance were noted, but management emphasized the importance of upcoming data releases and regulatory meetings for future growth.

Reported metrics

Guidance from management

Management maintained their guidance for the NeoLIPA study, expecting top-line results in the second half of 2026. No changes to overall financial guidance were indicated.

What management said

So we have built a quite strong clinical portfolio of results. And -- we are a strong belief of the capabilities of our technology and are very focused on bringing this to the patient as fast as possible. We have shared that Berica is moving towards a Phase III study. And we, with this result we see in advent melanoma, as melanoma, we are also now focused to bring ruxotemetide to or registrational study in melanoma. ...

Yes. Thank you, Austin. So the purpose of the meeting with the FDA is to align on the recessional plan. So this is really a typical step that we do before starting a registrational study. So we asked a lot of questions about the design study in that strategy. Regarding the time line, we are planning to have the meeting in the second half of this year.

What analysts pressed on

Analysts expressed concerns regarding the increase in operating expenses and the sustainability of the current cash position. There were questions about the timeline for the registrational trial and potential partnerships to support funding.

Main topics on the call

• ATLAS-IT-05 Study Results — Management reported that the ATLAS-IT-05 study demonstrated a significant abscopal effect in melanoma patients, with 'at least 90% of subjects still alive at the 1-year mark.' This finding is crucial as it suggests syste...
• Partnership with Verrica — Lytix confirmed that Verrica is preparing for a Phase III registrational trial with ruxotemitide in basal cell carcinoma, expected to start in 2026. This partnership is pivotal for expanding ruxotemitide's application be...
• Financial Position and Capital Raise — The company raised NOK 77.3 million in Q1 2026, increasing cash and short-term investments to NOK 120 million. This capital raise is expected to support ongoing clinical activities and strategic initiatives, enhancing fi...
• Upcoming FDA Meeting — Lytix plans to meet with the FDA in the second half of 2026 to align on the registrational trial design for ruxotemitide in neoadjuvant melanoma. This meeting is critical for future regulatory strategy and potential part...

Read the full Lytix Biopharma ASA transcript (Q1 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 14 Lytix Biopharma ASA earnings call transcripts on record, spanning August 31, 2023 to August 27, 2026. Based on this history, Lytix Biopharma ASA reports quarterly. The most recent call on file is dated August 27, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

LYTIX

Exchange

OB

Country

NO

Sector

Health Care

Industry

Biotechnology

Calls on record

14

First call

August 31, 2023

Most recent

August 27, 2026

Reporting cadence

quarterly